On September 30, 2021, Asada, Masaki; Higuchi, Satonori; Naganawa, Atsushi; Hanada, Keisuke; Takeda, Yasuhiro published a patent.HPLC of Formula: 59833-69-1 The title of the patent was Preparation of phenylacetic acid compound as DP receptor antagonist. And the patent contained the following:
Title compound I [R1 = H, alkyl or benzyl; R2-R4 = independently halo, alkyl (optionally substituted with halo) or alkoxy (optionally substituted with halo); J = bond, -O- or -S-; L = bond, alkylene, alkenylene, etc.; R5 = H, carbocyclyl or heterocyclyl (wherein the carbocycle and heterocycle are optionally substituted with R7); when L is a bond, R5 cannot be H; R7 = halo, alkyl (optionally substituted with halo) or alkoxy (optionally substituted with halo); R11 = H, halo or alkyl (optionally substituted with halo); R12 = H, halo or alkyl (optionally substituted with halo); R11 and R12, together with the carbon atom to which they are attached, may be combined to form a saturated carbocycle; n = 0-4; m = 0-3; or a pharmaceutically acceptable salt thereof] was prepared For example, treatment of Me (4-chloro-3-[2,6-dimethyl-4-[2-(oxan-2-yl)ethoxy]benzamido]phenyl)acetate with Lawesson’s reagent, chiral separation and hydrolsis afforded compound II. The phenylacetic acid compound in the present invention shows high antagonistic activity for DP receptor, e.g., IC50 value of II was 0.0048μM. Compound I is claimed useful for the treat,ent of allergic disease, inflammation, sleep disorder, etc. The experimental process involved the reaction of Methyl 2-(3-amino-4-chlorophenyl)acetate(cas: 59833-69-1).HPLC of Formula: 59833-69-1
The Article related to phenylacetic acid preparation dp receptor antagonist, allergy inflammation sleep disorder treatment phenylacetic acid, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Amides, Amidines, Imidic Esters, Hydrazides, and Hydrazonic Esters and other aspects.HPLC of Formula: 59833-69-1
Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics